• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The AREDS1: Zinc and antioxidant supplementation reduce progression of AMD in high-risk patients [The Classics Series]

byCarl ShenandAndrew Cheung, MD MBA
June 23, 2017
in General Medicine Classics, Surgery Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients with advanced age-related macular degeneration (AMD) in one eye only or intermediate AMD in either eye, zinc and antioxidant supplementation reduced the risk of progression to advanced AMD and reduced the risk of moderate vision loss.

2. In patients with early stage AMD, supplementation did not reduce the risk of progressing to advanced AMD. No supplementation is recommended in early stage AMD, as the baseline risk of progression is low.

Original Date of Publication: October 2001

Study Rundown: AMD is the leading cause of irreversible vision loss in the world in individuals 65 years of age and older. Until the Age-Related Eye Disease Study 1 (AREDS1), no therapies were available to prevent the progression of AMD. Epidemiologic and animal studies had suggested that zinc and antioxidant vitamins could potentially be beneficial in treating AMD by targeting and reducing oxidative stress.

The AREDS1 was a randomized controlled trial that sought primarily to evaluate the effects of high-dose zinc and antioxidants on the progression of AMD and vision loss. The study found that, in those at high-risk of developing advanced AMD, a combination of zinc and antioxidants reduced the risk by 25% and reduced the risk of moderate vision loss by 19%. In patients with no AMD or early AMD, there was no benefit observed with supplementation, though the risk of progression was low with placebo.

Click to read the study in JAMA Ophthalmology

In-Depth [randomized controlled trial]: This multicenter, randomized, controlled trial recruited patients between 55-80 years of age with a best-corrected visual acuity of ≥20/32 in the study eye and a range of AMD abnormalities (i.e., from no abnormalities to one eye with features of advanced AMD). Exclusion criteria included obscured ocular media preventing macular photographs, any eye disease that could complicate assessment of AMD, and previous ocular non-cataract surgery. A total of 3640 patients were assigned to 4 ordinal categories of AMD (1-4) based on the extent of their macular findings, and subsequently randomized 1:1:1:1 to treatment with 1) zinc alone, 2) antioxidants alone, 3) zinc and antioxidants, and 4) placebo. The antioxidant formulation was a combination of vitamin C, E, and beta carotene, while the zinc formulation consisted of zinc and cupric acid. Patients were followed for 5 years or longer. The primary outcomes were disease progression, treatment for advanced AMD, and visual acuity loss of ≥15 letters. A p-value ≤0.01 was considered statistically significant.

RELATED REPORTS

Faricimab noninferior to aflibercept for treatment of neovascular age-related macular degeneration

The AREDS2: No benefit from additional carotenoid and omega-3-fatty acid supplementation to original AREDS formulation [The Classics Series]

The CATT study: Avastin and Lucentis equally effective for macular degeneration [Classics Series]

Category 2 (early AMD), 3 (intermediate AMD), and 4 (advanced AMD in one eye) patients had a 1.3%, 18%, and 43% probability of progression to advanced AMD, respectively, in the placebo group by 5 years. Compared with placebo, zinc and antioxidant therapy led to significantly lower risk of progression to advanced AMD (OR 0.72; 99%CI 0.52-0.98, p = 0.007); the risk of progression was further reduced when category 1 and 2 patients were excluded from analysis (OR 0.66; 99%CI 0.47-0.91, p = 0.001). After excluding category 1 and 2 patients, zinc and antioxidant treatment also significantly reduced the risk of moderate vision loss compared to placebo (OR 0.73; 99%CI 0.54-0.99, p = 0.008).

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: age-related macular degenerationareds1
Previous Post

2 Minute Medicine Rewind June 19, 2017

Next Post

Cetuximab and bevacizumab are similar in combined platin therapy for advanced or metastatic colorectal cancer

RelatedReports

Blindness and visual impairment decreasing worldwide
Chronic Disease

Faricimab noninferior to aflibercept for treatment of neovascular age-related macular degeneration

March 9, 2022
Adverse pregnancy outcomes associated with thrombophilias [Classics Series]
General Medicine Classics

The AREDS2: No benefit from additional carotenoid and omega-3-fatty acid supplementation to original AREDS formulation [The Classics Series]

October 13, 2017
Classics Series, Landmark Trials in Medicine
General Medicine Classics

The CATT study: Avastin and Lucentis equally effective for macular degeneration [Classics Series]

January 21, 2015
Antioxidants, omega-3 lack benefit in age-related macular degeneration
Chronic Disease

Transplanted stem cells help restore sight in age-related macular degeneration

October 16, 2014
Next Post
Development of a risk index for colorectal cancer screening

Cetuximab and bevacizumab are similar in combined platin therapy for advanced or metastatic colorectal cancer

American Academy of Pediatrics recommends standards for adverse event disclosures

Fecal immunochemical testing demonstrates good diagnostic accuracy for high-risk individuals

Childhood illness linked to increased education gender gaps in LMICs

Childhood illness linked to increased education gender gaps in LMICs

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
  • Operating the day after performing surgery the previous night not associated with adverse patient outcomes
  • Gratitude-focused writing may improve mental wellness during periods of chronic stress
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.